Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206342 | 1.00 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL7096713 | 0.85 | TP53 (0.68) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL10712301 | 0.84 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9400389 | 0.83 | NPC1 (0.66) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL8497179 | 0.83 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1883373 | 0.83 | CA12 (0.71) | MEN1KMT2ANPC1POLBLMNA | |
| SCHEMBL1877777 | 0.82 | MEN1 (0.72) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1875397 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL31206219 | 0.82 | MEN1 (0.72) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL8497569 | 0.81 | POLB (0.66) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | claimed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | claimed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | claimed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | claimed |
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | SALL4, SAV1, SUMO1 | MEN1 574/4885KMT2A 972/4885NPC1 3795/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | MEN1 422/4885KMT2A 3423/4885NPC1 331/4885 |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | TP53, NUP205, ANXA5 | MEN1 2133/4885KMT2A 2664/4885NPC1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.